Advertisement

Topics

Sage soars as postpartum depression drug moves closer to approval

10:28 EST 9 Nov 2017 | Reuters

(Reuters) - Sage Therapeutics Inc's shares surged to a record on Thursday after its postpartum depression drug succeeded in two late-stage studies, paving the way for it to bring to market the first FDA-approved treatment for the disorder.

Original Article: Sage soars as postpartum depression drug moves closer to approval

NEXT ARTICLE

More From BioPortfolio on "Sage soars as postpartum depression drug moves closer to approval"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...